Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons

被引：0
作者：
Zeng, Hui-Ai [1 ]
Lv, Hui-Min [1 ]
Zhang, Meng-Wei [1 ]
Niu, Li-Min [1 ]
Wang, Jing [1 ]
Sun, Hui-Hui [1 ]
Liu, Zhen-Zhen [1 ]
Yan, Min [1 ]
机构：
[1] Zhengzhou Univ, Henan Breast Canc Ctr, Affiliated Canc Hosp, Dept Breast Dis, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2025年 / 151卷 / 02期
关键词：
Breast cancer; Real-world; Chemotherapy; Docetaxel; Rechallenge; RANDOMIZED PHASE-III; DRUG-RESISTANCE; THERAPY; ANTHRACYCLINE; CAPECITABINE; PACLITAXEL; SURVIVAL;
D O I：
10.1007/s00432-025-06133-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PurposeThis study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.Patients and methodsWe retrospectively analyzed HER2-negative MBC patients treated with docetaxel-based therapy (DBT) at our institution from 2010 to 2020. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were assessed. Multivariate Cox regression and propensity score matching analysis (PSMA) were used to minimize bias.ResultsAmong 600 patients, 369 only received docetaxel once (control group), while 231 (38.5%) received docetaxel rechallenge as second or later-line therapy (rechallenge group). In the second-line rechallenge subset (143 patients), ORR was 51.0%, and PFS was 6.7 months. Multivariate analysis showed that a response to initial DBT (stable disease [SD] vs. complete response/partial response [CR/PR]: odds ratio [OR] 2.615, 95% confidence interval [CI] 1.373-4.981; p = 0.03) independently predicted the ORR. Beyond second-line rechallenge, the ORR and PFS were 37.5% and 5.6 months, respectively. After PSMA, the rechallenge group demonstrated significantly improved OS compared to the control group: 50.5 months vs. 46.0 months (Hazard Ratio [HR] 0.632; 95% CI 0.455-0.878; p = 0.006). The toxicities reported were manageable, primarily hematologic, with grade 3-4 events occurring in 19.5% of cases.ConclusionThis study suggests that docetaxel rechallenge may be an effective and tolerable later-line treatment option for patients with HER2-negative MBC, particularly those who responded to initial DBT. However, further prospective, randomized controlled research is needed to fully evaluate its impact on disease response in this patient population.
引用
收藏
页数：12
相关论文
共 29 条
  • [1] Barroso-Sousa R., Vaz-Luis I., Di Meglio A., Hu J., Li T., Rees R., Sinclair N., Milisits L., Leone J.P., Constantine M., Faggen M., Briccetti F., Block C., Partridge A., Burstein H., Waks A.G., Tayob N., Trippa L., Tolaney S.M., Hassett M.J., Winer E.P., Lin N.U., Prospective study testing a simplified Paclitaxel Premedication Regimen in patients with early breast Cancer, Oncologist, 26, 11, pp. 927-933, (2021)
  • [2] Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., Andre F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., Boyle F., Cardoso M.J., Carey L.A., Cortes J., El Saghir N.S., Elzayat M., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Gligorov J., Haidinger R., Harbeck N., Hu X., Kaufman B., Kaur R., Kiely B.E., Kim S.B., Lin N.U., Mertz S.A., Neciosup S., Offersen B.V., Ohno S., Pagani O., Prat A., Penault-Llorca F., Rugo H.S., Sledge G.W., Thomssen C., Vorobiof D.A.,
  • [3] Fumoleau P., Chevallier B., Kerbrat P., Krakowski Y., Misset J.L., Maugard-Louboutin C., Dieras V., Azli N., Bougon N., Riva A., Roche H., A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the clinical Screening Group of the EORTC, Ann Oncol, 7, 2, pp. 165-171, (1996)
  • [4] Galletti G., Zhang C., Gjyrezi A., Cleveland K., Zhang J., Powell S., Thakkar P.V., Betel D., Shah M.A., Giannakakou P., Microtubule Engagement with Taxane is altered in taxane-resistant gastric Cancer, Clin Cancer Res, 26, 14, pp. 3771-3783, (2020)
  • [5] Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A., Bhar P., Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer, J Clin Oncol, 27, 22, pp. 3611-3619, (2009)
  • [6] Gradishar W.J., Moran M.S., Abraham J., Aft R., Agnese D., Allison K.H., Anderson B., Burstein H.J., Chew H., Dang C., Elias A.D., Giordano S.H., Goetz M.P., Goldstein L.J., Hurvitz S.A., Isakoff S.J., Jankowitz R.C., Javid S.H., Krishnamurthy J., Leitch M., Lyons J., Mortimer J., Patel S.A., Pierce L.J., Rosenberger L.H., Rugo H.S., Sitapati A., Smith K.L., Smith M.L., Soliman H., Stringer-Reasor E.M., Telli M.L., Ward J.H., Wisinski K.B., Young J.S., Burns J., Kumar R., Breast Cancer, Version
  • [7] Gradishar W.J., Moran M.S., Abraham J., Abramson V., Aft R., Agnese D., Allison K.H., Anderson B., Bailey J., Burstein H.J., Chen N., Chew H., Dang C., Elias A.D., Giordano S.H., Goetz M.P., Jankowitz R.C., Javid S.H., Krishnamurthy J., Leitch A.M., Kumar R., Breast Cancer, Version 3.2024, NCCN Clinical Practice guidelines in Oncology, J Natl Compr Cancer Netw JNCCN, 22, 5, pp. 331-357, (2024)
  • [8] Guo X., Loibl S., Untch M., Mobus V., Schwedler K., Fasching P.A., Barinoff J., Holms F., Thomssen C., Zahm D.M., Kreienberg R., Hauschild M., Eidtmann H., Tauchert S., Mehta K., von Minckwitz G., Re-challenging taxanes in recurrent breast Cancer in patients treated with (Neo-)Adjuvant taxane-based therapy, Breast Care (Basel), 6, 4, pp. 279-283, (2011)
  • [9] Hanovich E., Asmis T., Ong M., Stewart D., Rechallenge Strategy in Cancer Therapy, Oncology, 98, 10, pp. 669-679, (2020)
  • [10] Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G., Cancer drug resistance: an evolving paradigm, Nat Rev Cancer, 13, 10, pp. 714-726, (2013)
123